Capricor Entered into an Exclusive Commercialization and Distribution Agreement with Nippon Shinyaku for CAP-1002 to Treat Duchenne Muscular Dystrophy in Japan
Shots:
- Capricor will receive $12M up front, ~$89M in additional development & sales-based milestones along with a double-digit share of product revenue. The agreement will expand Nippon Shinyaku’s DMD franchise & advance the therapies for DMD patients
- If the product is authorized in Japan, Capricor will hold the marketing authorization, lead the clinical development & will sell the commercial products to Nippon Shinyaku. Nippon Shinyaku will lead the distribution of CAP-1002 in Japan
- CAP-1002 showed clinical benefits for cardiac & skeletal muscle myopathy while the 18 mos. OLE (HOPE-2) study showed evidence of disease modification & demonstrated significant differences in the performance of the upper limb
Ref: Globe Newswire | Image: Capricor
Related Newswire:- Capricor Therapeutics Publishes Results of CAP-1002 in P-II (HOPE-2) Trial for Late-Stage Duchenne Muscular Dystrophy in The Lancet
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
